Hemocompatibility evaluation of small elastomeric hollow fiber membranes as vascular substitutes

One of the main challenges for clinical implementation of small diameter vascular grafts (SDVGs) is their limited hemocompatibility. Important design specifications for such grafts include features that minimize the long-term risks of restenosis, fouling, and thrombus formation. In our lab, we have developed elastomeric hollow fiber membranes (HFMs), using a phase inversion method, as candidates for SDVGs. Here, we present our results for in vitro hemocompatibility testing of our HFM under flow and static conditions. Our results showed that the polymer-based HFMs do not damage the integrity of human red blood cells (RBCs) as shown by their low hemolytic extent (less than 2%). When analyzed for blood cell lysis using lactate dehydrogenase (LDH) activity as an indicator, no significant differences were observed between blood exposed to our HFMs and uncoagulated blood. Analysis of protein adsorption showed a low concentration of proteins deposited on the surfaces of HFM after 24 h. Platelet adhesion profiles using human platelet-rich plasma (PRP) showed that a low level of platelets adhered to the HFMs after 24 h, indicating minimal thrombotic potential. Under the majority of conditions, no significant differences were observed between medical-grade polymers and our HFMs. Eventual optimization of hemocompatible elastomeric HFM vessel grafts could lead to improved tissue vascularization as well as vascularized, tissue-engineered scaffolds for organ repair.